SIEN-NET Trademark

Trademark Overview


On Friday, November 8, 2019, a trademark application was filed for SIEN-NET with the United States Patent and Trademark Office. The USPTO has given the SIEN-NET trademark a serial number of 79274546. The federal status of this trademark filing is REGISTERED as of Tuesday, January 19, 2021. This trademark is owned by Sienna Cancer Diagnostics Ltd. The SIEN-NET trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, diagnostic kits consisting primarily of monoclonal antibodies used in the capture of specific biological markers for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical use, namely, for use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral, and bacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparations, reagents, and substances f...
sien-net

General Information


Serial Number79274546
Word MarkSIEN-NET
Filing DateFriday, November 8, 2019
Status700 - REGISTERED
Status DateTuesday, January 19, 2021
Registration Number6248001
Registration DateTuesday, January 19, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 3, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, diagnostic kits consisting primarily of monoclonal antibodies used in the capture of specific biological markers for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical use, namely, for use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral, and bacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparations, reagents, and substances for medical purposes; diagnostic products and testing materials for medical purposes, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in capturing and purifying specific biological markers for use in disease testing; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents for capturing and purifying specific biological markers that can be utilised in therapeutics or diagnostics; cells for growing recombinant human protein for medical purposes; recombinant DNA technology proteins for medical use; biological reagents for use in molecular biology, namely, reagents for medical use for capturing and purifying specific biological markers that contain nucleic acid; antibodies that are specifically able to bind and capture specific biological markers for medical purposes; antibody fragments that are specifically able to bind and capture specific biological markers for medical purposes; antibody conjugates that are specifically able to bind and capture specific biological markers for medical purposes; pharmaceutical preparations for the treatment, reconstruction and repair of antibodies; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 23, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSienna Cancer Diagnostics Ltd
Party Type30 - Original Registrant
Legal Entity Type83 - NOT AVAILABLE
AddressAU

Party NameSienna Cancer Diagnostics Ltd
Party Type20 - Owner at Publication
Legal Entity Type83 - NOT AVAILABLE
AddressAU

Party NameSienna Cancer Diagnostics Ltd
Party Type10 - Original Applicant
Legal Entity Type83 - NOT AVAILABLE
AddressAU

Trademark Events


Event DateEvent Description
Sunday, May 16, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 23, 2021FINAL DISPOSITION NOTICE SENT TO IB
Friday, April 23, 2021FINAL DISPOSITION PROCESSED
Monday, April 19, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, January 29, 2021CHANGE OF NAME/ADDRESS REC'D FROM IB
Tuesday, January 19, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, November 3, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 3, 2020PUBLISHED FOR OPPOSITION
Monday, November 2, 2020NOTIFICATION PROCESSED BY IB
Wednesday, October 14, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 14, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 14, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, September 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 10, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 9, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 9, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 27, 2020REFUSAL PROCESSED BY IB
Monday, March 9, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, March 9, 2020REFUSAL PROCESSED BY MPU
Wednesday, February 19, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 18, 2020NON-FINAL ACTION WRITTEN
Wednesday, February 12, 2020ASSIGNED TO EXAMINER
Friday, December 27, 2019APPLICATION FILING RECEIPT MAILED
Monday, December 23, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 19, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB